Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection

Findlater, Lucy; Trickey, Adam; Jones, Hayley E; Trindall, Amy; Taylor‐Phillips, Sian; Mulchandani, Ranya; Oliver, Isabel; Wyllie, David

doi:10.1128/spectrum.02468-22

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, studies correlating LFIAs results with the rate of protection would be useful. Interestingly, one study showed that positive IgG results on four different LFIAs were associated to a lower rate of subsequent SARS-CoV-2 infection, and these results were similar to those obtained with laboratory immunoassays [104] . However, this topic needs further investigation.…”

Section: Performance and Reliability Of Lfia In Post-infectionsupporting

confidence: 52%

“…In one recent systematic review it was shown that the sensitivity of LFIA after 21 days approached the sensitivity of the ELISA method [94] . Although the permanence of IgG after SARS-CoV-2 infection can be long-lasting, up to one year, the problem is that little is known on the reliability of LFIAs in detecting antibodies over the time (>30 days from the infection) and this would be important when conducting long-term surveillance among populations [104] , [108] . In one study a POC test for IgG exhibited a high sensitivity comparable to ELISA and CLIA up to 60 days from the infection [109] .…”

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

See 1 more Smart Citation

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

Section: Performance and Reliability Of Lfia In Post-infectionsupporting

confidence: 52%

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people

et al. 2023

View full text Add to dashboard Cite

The value of SARS-CoV-2 lateral flow immunoassay (LFIA) tests for estimating individual disease risk is unclear. The REACT-2 study in England, UK, obtained self-administered SARS-CoV-2 LFIA test results from 361,801 adults in January-May 2021. Here, we link to routine data on subsequent hospitalisation (to September 2021), and death (to December 2021). Among those who had received one or more vaccines, a negative LFIA is associated with increased risk of hospitalisation with COVID-19 (HR: 2.73 [95% confidence interval: 1.15,6.48]), death (all-cause) (HR: 1.59, 95% CI:1.07, 2.37), and death with COVID-19 as underlying cause (20.6 [1.83,232]). For people designated at high risk from COVID-19, who had received one or more vaccines, there is an additional risk of all-cause mortality of 1.9 per 1000 for those testing antibody negative compared to positive. However, the LFIA does not provide substantial predictive information over and above that which is available from detailed sociodemographic and health-related variables. Nonetheless, this simple test provides a marker which could be a valuable addition to understanding population and individual-level risk.

show abstract

Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection

Cited by 2 publications

References 28 publications

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people

Contact Info

Product

Resources

About